Alembic Pharma arm gets USFDA nod Treprostinil Injection

Alembic Pharma arm gets USFDA nod Treprostinil Injection

by admin- Friday, February 12th, 2021 07:58:21 PM

Alembic Pharmaceuticals announced that its wholly-owned subsidiary Alembic Global Holding SA has received final approval from USFDA for its Abbreviated New Drug Application Treprostinil Injection, 20 mg/20 ml (1 mg/ml), 50 mg/20 ml (2.5 mg/ml), 100 mg/20 ml (5 mg/ml), and 200 mg/20 ml (10 mg/ml), Multiple-Dose Vials.

News Updates